Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection
- 25 September 2012
- journal article
- review article
- Published by Springer Nature in Albrecht von Graefes Archiv für Ophthalmologie
- Vol. 250 (12), 1717-1723
- https://doi.org/10.1007/s00417-012-2159-5
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- INTRAVITREAL BEVACIZUMAB THERAPY ON AN AS-PER-NEEDED BASIS IN SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIARetina, 2011
- TWELVE-MONTH OUTCOME AFTER ONE INTRAVITREAL INJECTION OF BEVACIZUMAB TO TREAT MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?Albrecht von Graefes Archiv für Ophthalmologie, 2010
- Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularizationAlbrecht von Graefes Archiv für Ophthalmologie, 2008
- Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year ResultsAmerican Journal of Ophthalmology, 2008
- Myopic choroidal neovascularizationOphthalmology, 2003
- Prevalence and progression of myopic retinopathy in an older populationOphthalmology, 2002
- VEGF is major stimulator in model of choroidal neovascularization.2000
- Macular Complications Associated With Posterior StaphylomaAmerican Journal of Ophthalmology, 1997
- Visual Prognosis of Disciform Degeneration in MyopiaOphthalmology, 1983